PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancerAntonino Glaviano, Alan Prem Kumar, Aaron Song Chuan Foo et al.|Molecular Cancer|2023Cited by 1.9k
Myocardial Viability and Survival in Ischemic Left Ventricular DysfunctionRobert O. Bonow, Julio A. Panza, Gerald Maurer et al.|New England Journal of Medicine|2011Cited by 877
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trialJohann S. de Bono, Ulrik Lassen, Jean-Pascal Machiels et al.|The Lancet Oncology|2019Cited by 228
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trialKarim Fizazi, Mika Mustonen, Christophe Massard et al.|The Lancet Oncology|2014Cited by 194
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced CancerRobert H. Jones, Udai Banerji, Ruth Plummer et al.|Clinical Cancer Research|2022Cited by 41